Data gathered: November 23
AI Stock Analysis - Incyte (INCY)
Analysis generated June 17, 2024. Powered by Chat GPT.
Incyte Corporation (INCY) is a well-established biopharmaceutical company focused on the discovery, development, and commercialization of proprietary therapeutics. The firm's portfolio includes products aimed at treating various cancer types, inflammatory diseases, and more. Incyte leverages its strong research and development capabilities to maintain a competitive edge in an evolving market.
Stock Alerts - Incyte (INCY)
 |
Incyte | November 19 Price is down by -13.2% in the last 24h. |
|
Incyte | November 15 Price is down by -5.6% in the last 24h. |
|
Incyte | November 13 Web Traffic is up by 72.7% over the last month. |
|
Incyte | November 9 Insider Alert: Flannelly Barry P is selling shares |
Alternative Data for Incyte
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 51 | Sign up | Sign up | Sign up |
| Sentiment | 95 | Sign up | Sign up | Sign up |
| Webpage traffic | 67,000 | Sign up | Sign up | Sign up |
| Employee Rating | 78 | Sign up | Sign up | Sign up |
| Google Trends | 15 | Sign up | Sign up | Sign up |
| Patents | 516 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Facebook Engagement | 188 | Sign up | Sign up | Sign up |
| Facebook Followers | 4,720 | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 11 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 5,297 | Sign up | Sign up | Sign up |
| Twitter Followers | 6,503 | Sign up | Sign up | Sign up |
| Twitter Mentions | 27 | Sign up | Sign up | Sign up |
| Youtube Subscribers | 237 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 54 | Sign up | Sign up | Sign up |
| Linkedin Employees | 2,934 | Sign up | Sign up | Sign up |
About Incyte
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States, Europe, Japan, and internationally.
| Price | $71.72 |
| Target Price | Sign up |
| Volume | 1,520,000 |
| Market Cap | $13.6B |
| Year Range | $51.18 - $83.38 |
| Dividend Yield | 0% |
| PE Ratio | 782.11 |
| Analyst Rating | 40% buy |
| Industry | Biotechnology |
In the news
 |
Empowered Funds LLC Reduces Stock Position in Incyte Co. (NASDAQ:INCY)November 22 - ETF Daily News |
 |
Goldman Sachs: Incyte Corporation (INCY) Is A Top Growth Investor StockNovember 21 - Yahoo |
|
Cantor Fitzgerald Reaffirms “Neutral” Rating for Incyte (NASDAQ:INCY)November 21 - ETF Daily News |
Biotech Stock Roundup: SAGE, INCY Suffer Setbacks, JAZZ Wins Oncology Drug Approval & MoreNovember 21 - Yahoo |
|
 |
Incyte's $750 Million Escient Deal Faces Setback With Toxicology Issues In Two Investigational Drugs, Analyst Flags ChallengesNovember 19 - Biztoc.com |
 |
Incyte Collapses. Why Its $750 Million Escient Acquisition Now Looks ShatteredNovember 19 - Biztoc.com |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 1.14B | 86M | 1.05B | 106M | 180M | 1.070 |
| Q2 '24 | 1.04B | 93M | 951M | -445M | -367M | -1.820 |
| Q1 '24 | 880M | 61M | 820M | 170M | 114M | 0.640 |
| Q4 '23 | 1.01B | 70M | 943M | 201M | 294M | 1.060 |
| Q3 '23 | 918M | 60M | 858M | 171M | 261M | 1.100 |
Insider Transactions View All
| Flannelly Barry P filed to sell 60,298 shares at $82. November 8 '24 |
| Flannelly Barry P filed to sell 58,042 shares at $78.2. November 8 '24 |
| Tray Thomas filed to sell 24,443 shares at $63.4. September 16 '24 |
| Tray Thomas filed to sell 24,825 shares at $62.9. September 16 '24 |
| Dickinson Jonathan Elliott filed to sell 43,723 shares at $62.3. September 16 '24 |
Similar companies
Congress Trading View All
| Politician | Filing Date | Type | Size |
|---|---|---|---|
| Ro Khanna |
Oct 8, 24 | Sell | $1K - $15K |
| Rohit Khanna Democrat |
May 6, 24 | Sell | $1K - $15K |
| Rohit Khanna Democrat |
May 6, 24 | Sell | $1K - $15K |
Read more about Incyte (INCY) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, facebook engagement, facebook followers, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, youtube subscribers, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of Incyte?
The Market Cap of Incyte is $13.6B.
What is Incyte's PE Ratio?
As of today, Incyte's PE (Price to Earnings) ratio is 782.11.
What is the current stock price of Incyte?
Currently, the price of one share of Incyte stock is $71.72.
How can I analyze the INCY stock price chart for investment decisions?
The INCY stock price chart above provides a comprehensive visual representation of Incyte's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Incyte shares. Our platform offers an up-to-date INCY stock price chart, along with technical data analysis and alternative data insights.
Does INCY offer dividends to its shareholders?
As of our latest update, Incyte (INCY) does not offer dividends to its shareholders. Investors interested in Incyte should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Incyte?
Some of the similar stocks of Incyte are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.